IHI vs PINK

Key Takeaways

• IHI is a passive ETF tracking the Dow Jones U.S. Select Medical Equipment Index, offering concentrated exposure to 47 medical device companies, while PINK is an actively managed fund targeting 50-100 innovative health care firms across biotech, medtech, and related areas.
• IHI features top holdings like ISRG (16.53%), ABT (16.06%), and SYK (11.04%), with 100% sector allocation to health care equipment; PINK's leaders include UTHR (8.14%), PCT (6.71%), and ALGN (5.87%), with ~93% in health care.
• Expense ratios differ at 0.38% for IHI (lower cost) versus 0.51% for PINK, reflecting passive versus active management.
• IHI provides higher liquidity with average daily volume over 2 million shares; PINK offers a unique pro bono structure, donating net profits to Susan G. Komen.
• Both ETFs target health care growth but IHI emphasizes established device makers for stability, while PINK seeks higher-growth innovators with broader diversification.
• Risk profiles vary: IHI's concentration in top holdings (75% in top 10) may amplify sector-specific volatility; PINK's active approach allows tactical adjustments amid biotech trends.

Introduction

In the evolving health care landscape, investors seek targeted exposure to medical innovation amid aging populations, technological advances, and rising demand for treatments. The IHI and PINK ETFs represent complementary yet distinct strategies within this sector. IHI delivers precise, passive access to U.S. medical device leaders, capitalizing on procedural growth and diagnostics. PINK, actively managed, pursues broader health care innovators including biotech and gene therapy, aiming for outsized returns through stock selection. Comparing them highlights trade-offs in focus, costs, and risk, aiding decisions on sector rotation or portfolio diversification in recent market cycles.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passive fund seeking to track the Dow Jones U.S. Select Medical Equipment Index, composed of U.S. equities in the medical devices subsector. Launched in 2006, it holds 47 stocks, with top holdings including ISRG (Intuitive Surgical, Inc., 16.53%), ABT (Abbott Laboratories, 16.06%), SYK (Stryker Corporation, 11.04%), EW (Edwards Lifesciences Corporation, 4.98%), and IDXX (IDEXX Laboratories, Inc., 4.74%). The top 10 account for about 75% of assets.

Sector allocation is 100% health care, focused on equipment and supplies. The expense ratio is 0.38%, with assets under management (AUM, a measure of fund size) around $3 billion. High liquidity is evident in average daily volume exceeding 2 million shares and a tight 0.02% median bid-ask spread. The index rebalances periodically to reflect market-cap weighting, ensuring structural purity in medical device exposure without active bets.

Simplify Health Care ETF (PINK) Overview

The Simplify Health Care ETF (PINK) is an actively managed fund pursuing long-term capital appreciation through exposure to 50-100 U.S. health care companies, emphasizing biotech, medtech, gene therapy, and cost-reducing innovators per Global Industry Classification Standard (GICS) definitions. Launched in 2021, it holds approximately 52 stocks, with top positions like UTHR (United Therapeutics Corporation, 8.14%), PCT (PureCycle Technologies, Inc., 6.71%), ALGN (Align Technology, Inc., 5.87%), NVO (Novo Nordisk A/S, 5.75%), and JNJ (Johnson & Johnson, 5.55%). The top 10 comprise 52.69% of assets.

Sector breakdown is predominantly health care (92.73%), with minor industrials (7.27%). The expense ratio stands at 0.51%, reflecting active management, with AUM near $250 million. Liquidity includes a 0.20% median bid-ask spread and daily volume around 25,000 shares. A distinguishing feature is its pro bono model: net profits are donated to Susan G. Komen, with over $350,000 contributed to date. No fixed index or rebalancing schedule; portfolio adjusts via manager discretion.

Industry and Thematic Backdrop

The health care sector benefits from structural tailwinds like demographic aging, chronic disease prevalence, and technological leaps in robotics, diagnostics, and therapies. Medical devices (IHI's focus) thrive on elective procedures rebounding post-pandemic and minimally invasive innovations, though facing reimbursement pressures and supply chain risks. Broader health care (PINK's domain) rides biotech funding cycles, GLP-1 drug momentum, and gene editing advances, tempered by regulatory hurdles from the FDA (Food and Drug Administration) and patent cliffs.

Recent capital flows favor defensive growth amid macro uncertainty, with interest rate expectations influencing valuations. Sector risks include policy shifts like drug pricing reforms and geopolitical tensions affecting semiconductors for devices. Both ETFs position for innovation-driven cycles, but devices offer stability while biotech adds volatility tied to clinical outcomes.

Performance and Positioning Comparison

In recent weeks and months, IHI has shown resilience tied to steady device demand from leaders like ISRG and ABT, benefiting from sector rotation toward quality growth amid earnings beats in procedures. Its lower beta (around 0.90) reflects moderated volatility compared to broader health care.

PINK, with active tilts toward high-conviction names like UTHR and NVO, has navigated biotech swings via tactical shifts, potentially capturing upside from drug approvals but exposing to higher drawdowns. Relative to IHI, PINK exhibits greater dispersion linked to innovation momentum and rate-sensitive small-caps. Both lag mega-cap tech in rallies but outperform cyclicals, with IHI's concentration amplifying device-specific trends versus PINK's diversified bets.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes like health care ETFs.

Tickeron AI Verdict

Tickeron’s AI currently favors IHI with moderate conviction (60-70% probability of relative outperformance over 3-6 months). This stems from its cost efficiency (0.38% expense ratio), superior liquidity, established track record, and concentrated exposure to stable medical device leaders amid consistent sector momentum. PINK's active strategy and innovation tilt offer upside potential but carry higher costs, turnover (201%), and volatility from biotech bets, better suited for risk-tolerant allocations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations